325 completed, 139 recruiting, 137 unknown, 47 terminated. 148 Phase 2, 133 Not applicable, 63 Phase 1, 58 Phase 3, 53 Phase 4.
Follow Adrenal Gland Diseases: new trials by email Literature Review of Adrenal Gland Diseases trials Research Report on Adrenal Gland Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IT and IV Lentiviral Gene Therapy for X-ALD Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy | Not applicable | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams. - Hypertension | Phase 4 | Not yet recruiting | Ottawa Hospital Research Institute | 30 | 2027-01-01 | 2026-10-14 |
| Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia exposure to healthcare transition protocol - Congenital Adrenal Hyperplasia | Not yet recruiting | University of Alabama at Birmingham | 40 | 2027-01-01 | 2026-10-14 | |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) NBIP-01435 - Congenital Adrenal Hyperplasia | Phase 2 | Not yet recruiting | Neurocrine Biosciences | 36 | 2026-12-01 | 2026-09-30 |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma Surgical resection, Preoperative RT - Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC) | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2026-10-27 | 2026-10-22 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-10-27 | 2026-10-22 |
| [11C]Metomidate PET-CT vs Usual Care for People With Primary Aldosteronism: a Proof-of-concept Study [11C] Metomidate PETCT, Adrenal Venous Sampling - Primary Aldosteronism | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 32 | 2026-10-01 | 2026-09-11 |
| An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia Asedebart - Adrenal Hyperplasia, Congenital | Phase 2 | Not yet recruiting | H. Lundbeck A/S | 45 | 2026-10-01 | 2026-10-05 |
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| Comparing Inclisiran Versus Statin for Primary Aldosteronism inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism | Not applicable | Recruiting | Third Military Medical University | 50 | 2026-10-01 | 2026-10-21 |
| Regular Sauna Use to Lower Blood Pressure in Primary Aldosteronism sauna session - Primary Aldosteronism, Hypertension | Not applicable | Not yet recruiting | University of Calgary | 10 | 2026-09-30 | 2026-08-31 |
| Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism baxdrostat - Primary Aldosteronism | Not applicable | Not yet recruiting | Queen Mary University of London | 30 | 2026-09-15 | 2026-09-02 |
| Hydrocortisone Versus Methylprednisolone for the Treatment of Glucocorticoid-Induced Adrenal Insufficiency Patients will receive 3 mg of methylprednisolone once daily. The dose is administered in the morning (1 ½ tablets of 2 mg Medrol after breakfast)., Patients will receive 15 mg of hydrocortisone daily. The dose is split into 10 mg in the morning after breakfast and 5 mg after 6-7 hours. - Adrenal Insufficiency | Phase 4 | Not yet recruiting | University Medical Centre Ljubljana | 66 | 2026-09-01 | 2026-07-14 |
| Thyroid Health Outcomes Registry for Surgery Thyroid Diseases, Thyroid Neoplasms | Not yet recruiting | Pirogov Russian National Research Medical University | 3000 | 2026-09-01 | 2026-09-10 | |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620 OMS1620, Placebo - Congenital Adrenal Hyperplasia (CAH) | Phase 1 | Not yet recruiting | OMass Therapeutics Australia Proprietary Ltd | 84 | 2026-09-01 | 2026-09-09 |
| Evaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia, Adrenal Insufficiency | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-09-01 | 2026-07-21 | |
| The ARISE Trial Compares Whether Giving Routine Steroid Replacement or Using Targeted Blood Tests to Guide Replacement Better Protects Certain Patients From Adrenal Insufficiency After the Removal of a Diseased Adrenal Gland. Empirical Hydrocortisone Protocol, Targeted Treatment Protocol - Adrenal Gland Disease | Not applicable | Not yet recruiting | King's College Hospital NHS Trust | 96 | 2026-09-01 | 2026-04-30 |
| Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome Osilodrostat, Placebo - Hypertension, Hypercortisolemia | Phase 4 | Not yet recruiting | RECORDATI GROUP | 63 | 2026-08-01 | 2025-12-10 |
| Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids. ACTH stimulation test, Cortisol - Reumatoid Arthritis, Corticosteroids Adverse Reaction | Recruiting | Bursa Yuksek Ihtisas Training and Research Hospital | 120 | 2026-07-31 | 2026-10-08 |
Showing 20 of 751. Sign in to see all of them.
Hyperaldosteronism (191) · Adrenal Insufficiency (132) · Cushing Syndrome (117) · Adrenal Hyperplasia, Congenital (99) · Adrenocortical Carcinoma (94) · Hypertension (64) · Adrenal Gland Neoplasms (62) · Adrenoleukodystrophy (62) · Addison Disease (35) · ACTH Syndrome, Ectopic (32) · Adrenal Cortex Neoplasms (30) · Pheochromocytoma (30) · Pituitary ACTH Hypersecretion (22) · Endocrine System Diseases (20)
Endocrine System Diseases (731) · Adrenocortical Hyperfunction (294) · Nutritional and Metabolic Diseases (223) · Neoplasms (217) · Metabolic Diseases (206) · Neoplasms by Site (202) · Endocrine Gland Neoplasms (191) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (186) · Genetic Diseases, Inborn (177) · Urogenital Diseases (164) · Female Urogenital Diseases and Pregnancy Complications (161) · Female Urogenital Diseases (160) · Male Urogenital Diseases (154) · Metabolism, Inborn Errors (154)
Hydrocortisone (46) · Spironolactone (16) · Adrenalectomy (15) · Dexamethasone (13) · Osilodrostat (13) · Mitotane (10) · Cisplatin (9) · Cosyntropin (8) · Eplerenone (8) · Magnetic Resonance Spectroscopy (8) · Prednisolone (8) · Prednisone (8) · pembrolizumab (8) · Blood Specimen Collection (7) · Mifepristone (7)
National Cancer Institute (NCI) (25) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (17) · Corcept Therapeutics (16) · Neurocrine UK Limited (15) · Assistance Publique - Hôpitaux de Paris (14) · Haukeland University Hospital (14) · Chongqing Medical University (13) · Third Military Medical University (11) · University of Wuerzburg (10) · Wuerzburg University Hospital (10) · National Taiwan University Hospital (9) · M.D. Anderson Cancer Center (8) · Qifu Li (8) · Seoul National University Hospital (8) · University of Roma La Sapienza (8)
United States (269) · China (97) · France (85) · Italy (82) · Germany (67) · United Kingdom (63) · Netherlands (47) · Canada (34) · Spain (32) · Sweden (23) · Poland (21) · Australia (19) · Brazil (19) · Denmark (18) · Israel (16)
Lynnette K Nieman, M.D. (9) · Martin Fassnacht, MD (7) · Deborah P Merke, M.D. (5) · Paul Orchard, MD (5) · Bruno Allolio, MD (4) · Stefanie Hahner, MD, Prof. (4) · Alfredo Berruti, MD (3) · Jaydira Del Rivero, M.D. (3) · Joanne Kurtzberg, MD (3) · Karim Meeran, MBBS BSc MD (3) · Naris Nilubol, M.D. (3) · Ulla Feldt-Rasmussen, Professor (3)
PMID 26934393, PMID 32327102, PMID 17161262, PMID 15657580, PMID 22551107, PMID 28385310, PMID 28576687, PMID 29279316, PMID 32206838, PMID 35218017, PMID 36795418, PMID 21828936, PMID 25968622, PMID 29987110, PMID 32890265, PMID 33527139, PMID 35418526, PMID 39383458, PMID 16172198, PMID 16508586, PMID 16670162, PMID 17554118, PMID 18539224, PMID 19349554, PMID 20580485, PMID 21270113, PMID 21586746, PMID 22146510, PMID 22154461, PMID 22743644, PMID 22997446, PMID 25002246, PMID 25013998, PMID 25559399, PMID 26507877, PMID 26760044, PMID 27315757, PMID 27325147, PMID 29129575, PMID 29229498, PMID 30255616, PMID 30590677, PMID 31476901, PMID 31536622, PMID 33196558, PMID 33447758, PMID 33605538, PMID 33796078, PMID 34146101, PMID 34398686
2018 (5), 2023 (5), 2009 (4), U10CA098543 (4), 2016 (3), 2025 (3), 2015 (2), N01CM00038 (2), U10CA180886 (2), 2014 (1), 2019 (1), K23DK142038 (1), K23NS087151 (1), M01RR001070 (1), N01CM00070 (1)